{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:45:43Z","timestamp":1788407143080,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Medical Research Council (NMRC) Transition Award","award":["TA24jul-0008"],"award-info":[{"award-number":["TA24jul-0008"]}]},{"name":"CSDU Clinician-Scientist Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"DOI":"10.1007\/s00392-025-02800-7","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:14:53Z","timestamp":1764832493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Natural history and outcomes of medically treated coronary artery disease: insights from reconstructed individual patient data of 29 randomized trials"],"prefix":"10.1007","author":[{"given":"Rishabh","family":"Mahesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien Hao Chen","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickram Vijay","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius Kai Ern","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen Zhiwen","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunrui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andie Djohan","family":"Hartanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Wen","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh Yang","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Weight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma A.","family":"Figtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poay Huan","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yip Han","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-0430","authenticated-orcid":false,"given":"Nicholas W. S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2800_CR1","unstructured":"Brown JC, Gerhardt TE, Kwon E. Risk factors for coronary artery disease: StatPearls Publishing, Treasure Island (FL); 2023 2023."},{"key":"2800_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae281","author":"B Chong","year":"2024","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW et al (2024) Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwae281","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2800_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-019-0233-y","volume":"17","author":"KAA Fox","year":"2020","unstructured":"Fox KAA, Metra M, Morais J, Atar D (2020) The myth of \u2018stable\u2019 coronary artery disease. Nat Rev Cardiol 17(1):9\u201321","journal-title":"Nat Rev Cardiol"},{"issue":"38","key":"2800_CR4","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34(38):2949\u20133003","journal-title":"Eur Heart J"},{"issue":"3","key":"2800_CR5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/oby.23658","volume":"31","author":"G Kong","year":"2023","unstructured":"Kong G, Chin YH, Lim J, Ng CH, Kannan S, Chong B et al (2023) A two-decade population-based study on the effect of hypertension in the general population with obesity in the United States. Obesity 31(3):832\u2013840","journal-title":"Obesity"},{"key":"2800_CR6","doi-asserted-by":"crossref","unstructured":"Alebna Pamela L, Han Chin Y, Ambrosio M, Kong G, Cyrus John W, Harley K, et al. Association of lipoprotein(a) with major adverse cardiovascular events across hs-CRP. JACC: Advances. 2024;3(12_Part_1):101409.","DOI":"10.1016\/j.jacadv.2024.101409"},{"issue":"7521","key":"2800_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/bmj.38603.656076.63","volume":"331","author":"TC Clayton","year":"2005","unstructured":"Clayton TC, Lubsen J, Pocock SJ, Vok\u00f3 Z, Kirwan BA, Fox KA, Poole-Wilson PA (2005) Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ 331(7521):869","journal-title":"BMJ"},{"issue":"3","key":"2800_CR8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","volume":"35","author":"NWS Chew","year":"2023","unstructured":"Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH et al (2023) The global burden of metabolic disease: data from 2000 to 2019. Cell Metab 35(3):414\u201328.e3","journal-title":"Cell Metab"},{"issue":"4","key":"2800_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041773","volume":"18","author":"AF Alshammary","year":"2021","unstructured":"Alshammary AF, Alharbi KK, Alshehri NJ, Vennu V, Ali KI (2021) Metabolic syndrome and coronary artery disease risk: a meta-analysis of observational studies. Int J Environ Res Public Health 18(4):1773","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"2800_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/CIRCULATIONAHA.120.048194","volume":"142","author":"S Bangalore","year":"2020","unstructured":"Bangalore S, Maron DJ, Stone GW, Hochman JS (2020) Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation 142(9):841\u2013857","journal-title":"Circulation"},{"issue":"15","key":"2800_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503\u20131516","journal-title":"N Engl J Med"},{"issue":"15","key":"2800_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O\u2019Brien SM, Boden WE et al (2020) Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 382(15):1395\u20131407","journal-title":"N Engl J Med"},{"issue":"24","key":"2800_CR13","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"RL Frye","year":"2009","unstructured":"Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360(24):2503\u20132515","journal-title":"N Engl J Med"},{"key":"2800_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3859","volume":"348","author":"S Windecker","year":"2014","unstructured":"Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M et al (2014) Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 348:g3859","journal-title":"BMJ"},{"issue":"1","key":"2800_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-03997-7","volume":"24","author":"L Bi","year":"2024","unstructured":"Bi L, Geng Y, Wang Y, Li S, Sun K, Guo Y et al (2024) An updated meta-analysis of optimal medical therapy with or without invasive therapy in patients with stable coronary artery disease. BMC Cardiovasc Disord 24(1):335","journal-title":"BMC Cardiovasc Disord"},{"key":"2800_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"9","key":"2800_CR17","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH et al (2023) 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 148(9):e9\u2013e119","journal-title":"Circulation"},{"key":"2800_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"2800_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4):404\u2013413","journal-title":"Biometrika"},{"issue":"3","key":"2800_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jrsm.1348","volume":"10","author":"G Schwarzer","year":"2019","unstructured":"Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R\u00fccker G (2019) Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 10(3):476\u2013483","journal-title":"Res Synth Methods"},{"issue":"4","key":"2800_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160","journal-title":"Evid Based Ment Health"},{"key":"2800_CR22","doi-asserted-by":"crossref","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Boca Raton, FL and London: Chapman & Hall\/CRC Press; 2021 2021.","DOI":"10.1201\/9781003107347"},{"key":"2800_CR23","unstructured":"JPT H, J T, J C, M C, T L, MJ P, VA W. Cochrane handbook for systematic reviews of interventions. Cochrane, 2023. 2024;Version 6.4."},{"issue":"1","key":"2800_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12(1):9","journal-title":"BMC Med Res Methodol"},{"key":"2800_CR25","unstructured":"Rohatgi A. WebPlotDigitizer [Available from: https:\/\/automeris.io."},{"key":"2800_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"1","key":"2800_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM199201023260102","volume":"326","author":"AF Parisi","year":"1992","unstructured":"Parisi AF, Folland ED, Hartigan P (1992) A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 326(1):10\u201316","journal-title":"N Engl J Med"},{"key":"2800_CR28","doi-asserted-by":"crossref","unstructured":"Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a veterans affairs cooperative randomized trial. This study was supported by the Cooperative Studies Program (study no. 267) of the U.S. Department of Veterans Affairs, Washington, D.C. Journal of the American College of Cardiology. 1997;29(7):1505\u201311.","DOI":"10.1016\/S0735-1097(97)00097-1"},{"issue":"12","key":"2800_CR29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0002-9149(98)00685-7","volume":"82","author":"PM Hartigan","year":"1998","unstructured":"Hartigan PM, Giacomini JC, Folland ED, Parisi AF (1998) Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Am J Cardiol 82(12):1445\u20131450","journal-title":"Am J Cardiol"},{"issue":"2","key":"2800_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199907083410202","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Waters D, Brown William V, van Boven Ad J, Schwartz L, Title Lawrence M et al (1999) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 341(2):70\u20136","journal-title":"N Engl J Med"},{"issue":"25","key":"2800_CR31","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.913111","volume":"120","author":"BR Chaitman","year":"2009","unstructured":"Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S et al (2009) The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 120(25):2529\u20132540","journal-title":"Circulation"},{"issue":"9641","key":"2800_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807\u2013816","journal-title":"Lancet"},{"issue":"26","key":"2800_CR33","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM198506273122603","volume":"312","author":"E Passamani","year":"1985","unstructured":"Passamani E, Davis KB, Gillespie MJ, Killip T (1985) A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 312(26):1665\u20131671","journal-title":"N Engl J Med"},{"issue":"16","key":"2800_CR34","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa043526","volume":"352","author":"JT Grayston","year":"2005","unstructured":"Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD et al (2005) Azithromycin for the secondary prevention of coronary events. N Engl J Med 352(16):1637\u20131645","journal-title":"N Engl J Med"},{"issue":"5","key":"2800_CR35","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/01.CIR.82.5.1629","volume":"82","author":"EL Alderman","year":"1990","unstructured":"Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T et al (1990) Ten-year follow-up of survival and myocardial infarction in the randomized coronary artery surgery study. Circulation 82(5):1629\u20131646","journal-title":"Circulation"},{"issue":"2","key":"2800_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/acm.2020.0361","volume":"27","author":"D Wang","year":"2021","unstructured":"Wang D, Li C, Xu X, Xu H, Guo C, Wang J et al (2021) Effect of Yugengtongyu granules in patients with stable coronary artery disease on reducing adverse cardiovascular events: a double-blind controlled trial. J Altern Complement Med 27(2):142\u2013149","journal-title":"J Altern Complement Med"},{"key":"2800_CR37","doi-asserted-by":"publisher","first-page":"1014664","DOI":"10.3389\/fcvm.2022.1014664","volume":"9","author":"SA Juricic","year":"2023","unstructured":"Juricic SA, Stojkovic SM, Galassi AR, Stankovic GR, Orlic DN, Vukcevic VD et al (2023) Long-term follow-up of patients with chronic total coronary artery occlusion previously randomized to treatment with optimal drug therapy or percutaneous revascularization of chronic total occlusion (COMET-CTO). Front Cardiovasc Med 9:1014664","journal-title":"Front Cardiovasc Med"},{"issue":"20","key":"2800_CR38","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa1505532","volume":"373","author":"SP Sedlis","year":"2015","unstructured":"Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB et al (2015) Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med 373(20):1937\u20131946","journal-title":"N Engl J Med"},{"issue":"2","key":"2800_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ehj.2012.10.002","volume":"65","author":"M Sadaka","year":"2013","unstructured":"Sadaka M, Loutfy M, Sobhy M (2013) Partial revascularization plus medical treatment versus medical treatment alone in patients with multivessel coronary artery disease not eligible for CABG. Egypt Heart J 65(2):57\u201364","journal-title":"Egypt Heart J"},{"issue":"26","key":"2800_CR40","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/eurheartj\/ehy220","volume":"39","author":"GS Werner","year":"2018","unstructured":"Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V et al (2018) A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 39(26):2484\u20132493","journal-title":"Eur Heart J"},{"issue":"9386","key":"2800_CR41","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386):782\u2013788","journal-title":"Lancet"},{"issue":"8122","key":"2800_CR42","first-page":"889","volume":"1","author":"European Coronary Surgery Study Group","year":"1979","unstructured":"European Coronary Surgery Study Group (1979) Coronary-artery bypass surgery in stable angina pectoris: survival at two years. Lancet 1(8122):889\u2013893","journal-title":"Lancet"},{"issue":"6","key":"2800_CR43","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM198808113190603","volume":"319","author":"E Varnauskas","year":"1988","unstructured":"Varnauskas E (1988) Twelve-year follow-up of survival in the randomized European coronary surgery study. N Engl J Med 319(6):332\u2013337","journal-title":"N Engl J Med"},{"issue":"11","key":"2800_CR44","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1205361","volume":"367","author":"B De Bruyne","year":"2012","unstructured":"De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367(11):991\u20131001","journal-title":"N Engl J Med"},{"issue":"3","key":"2800_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1803538","volume":"379","author":"P Xaplanteris","year":"2018","unstructured":"Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL et al (2018) Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med 379(3):250\u2013259","journal-title":"N Engl J Med"},{"issue":"4","key":"2800_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1056\/NEJM197901253000401","volume":"300","author":"FE Kloster","year":"1979","unstructured":"Kloster FE, Kremkau EL, Ritzmann LW, Rahimtoola SH, R\u00f6sch J, Kanarek PH (1979) Coronary bypass for stable angina: a prospective randomized study. N Engl J Med 300(4):149\u2013157","journal-title":"N Engl J Med"},{"issue":"13","key":"2800_CR47","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCULATIONAHA.120.049755","volume":"144","author":"HR Reynolds","year":"2021","unstructured":"Reynolds HR, Shaw LJ, Min JK, Page CB, Berman DS, Chaitman BR et al (2021) Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity. Circulation 144(13):1024\u20131038","journal-title":"Circulation"},{"issue":"5","key":"2800_CR48","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jcin.2008.08.002","volume":"1","author":"K Nishigaki","year":"2008","unstructured":"Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I et al (2008) Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv 1(5):469\u2013479","journal-title":"JACC Cardiovasc Interv"},{"issue":"43","key":"2800_CR49","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1093\/eurheartj\/eht201","volume":"34","author":"CL Garzillo","year":"2013","unstructured":"Garzillo CL, Hueb W, Gersh BJ, Lima EG, Rezende PC, Hueb AC et al (2013) Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial. Eur Heart J 34(43):3370\u20133377","journal-title":"Eur Heart J"},{"issue":"10","key":"2800_CR50","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.109.911669","volume":"122","author":"W Hueb","year":"2010","unstructured":"Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC et al (2010) Ten-year follow-up survival of the medicine, angioplasty, or surgery study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 122(10):949\u2013957","journal-title":"Circulation"},{"issue":"9","key":"2800_CR51","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/CIRCULATIONAHA.106.625475","volume":"115","author":"W Hueb","year":"2007","unstructured":"Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB et al (2007) Five-year follow-up of the medicine, angioplasty, or surgery study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9):1082\u20131089","journal-title":"Circulation"},{"issue":"10","key":"2800_CR52","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/j.jacc.2003.08.065","volume":"43","author":"W Hueb","year":"2004","unstructured":"Hueb W, Soares PR, Gersh BJ, C\u00e9sar LA, Luz PL, Puig LB et al (2004) The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 43(10):1743\u20131751","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2800_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ahj.2013.04.017","volume":"166","author":"EG Lima","year":"2013","unstructured":"Lima EG, Hueb W, Garcia RM, Pereira AC, Soares PR, Favarato D et al (2013) Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the medicine, angioplasty, or surgery study II (MASS II) trial. Am Heart J 166(2):250\u2013257","journal-title":"Am Heart J"},{"issue":"6","key":"2800_CR54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/icvts\/ivu288","volume":"19","author":"P Mansur Ade","year":"2014","unstructured":"Mansur Ade P, Hueb WA, Takada JY, Avakian SD, Soares PR, Garzilo CL et al (2014) Long-term follow-up of a randomized, controlled clinical trial of three therapeutic strategies for multivessel stable coronary artery disease in women. Interact Cardiovasc Thorac Surg 19(6):997\u20131001","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"7","key":"2800_CR55","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/0735-1097(95)00384-3","volume":"26","author":"WA Hueb","year":"1995","unstructured":"Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, Pileggi F (1995) The medicine, angioplasty or surgery study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26(7):1600\u20131605","journal-title":"J Am Coll Cardiol"},{"key":"2800_CR56","doi-asserted-by":"crossref","unstructured":"Hueb WA, Soares PR, Almeida De Oliveira S, Ari\u00ea S, Cardoso RH, Wajsbrot DB, et al. Five-year follow-op of the medicine, angioplasty, or surgery study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. Circulation. 1999;100(19 Suppl):Ii107\u201313.","DOI":"10.1161\/01.CIR.100.suppl_2.II-107"},{"issue":"10115","key":"2800_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","volume":"391","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J et al (2018) Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 391(10115):31\u201340","journal-title":"Lancet"},{"issue":"20","key":"2800_CR58","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"E Braunwald","year":"2004","unstructured":"Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J et al (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351(20):2058\u20132068","journal-title":"N Engl J Med"},{"issue":"10438","key":"2800_CR59","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(24)00413-6","volume":"403","author":"SJ Park","year":"2024","unstructured":"Park SJ, Ahn JM, Kang DY, Yun SC, Ahn YK, Kim WJ et al (2024) Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet 403(10438):1753\u20131765","journal-title":"Lancet"},{"key":"2800_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2019.102209","volume":"47","author":"J Li","year":"2019","unstructured":"Li J, Gao Z, Zhang L, Li S, Yang Q, Shang Q et al (2019) Qing-Xin-Jie-Yu granule for patients with stable coronary artery disease (QUEST trial): a multicenter, double-blinded, randomized trial. Complement Ther Med 47:102209","journal-title":"Complement Ther Med"},{"issue":"7","key":"2800_CR61","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S0735-1097(03)00951-3","volume":"42","author":"RA Henderson","year":"2003","unstructured":"Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DA (2003) Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 42(7):1161\u20131170","journal-title":"J Am Coll Cardiol"},{"key":"2800_CR62","doi-asserted-by":"crossref","unstructured":"Coronary angioplasty versus medical therapy for angina: the second randomised intervention treatment of angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350(9076):461\u20138.","DOI":"10.1016\/S0140-6736(97)07298-X"},{"issue":"18","key":"2800_CR63","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY et al (2014) Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370(18):1702\u20131711","journal-title":"N Engl J Med"},{"issue":"1","key":"2800_CR64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0735-1097(96)00122-2","volume":"28","author":"T Von Arnim","year":"1996","unstructured":"Von Arnim T (1996) Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the total ischemic burden bisoprolol study (TIBBs) follow-up. J Am Coll Cardiol 28(1):20\u201324","journal-title":"J Am Coll Cardiol"},{"key":"2800_CR65","doi-asserted-by":"crossref","unstructured":"Eighteen-year follow-up in the veterans affairs cooperative study of coronary artery bypass surgery for stable angina. Circulation. 1992;86(1):121\u201330.","DOI":"10.1161\/01.CIR.86.1.121"},{"issue":"10117","key":"2800_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","volume":"391","author":"SJ Connolly","year":"2018","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F et al (2018) Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):205\u2013218","journal-title":"Lancet"},{"key":"2800_CR67","doi-asserted-by":"crossref","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292(18):2217\u20132225","DOI":"10.1001\/jama.292.18.2217"},{"key":"2800_CR68","doi-asserted-by":"crossref","unstructured":"Varnauskas E et al (1979) Coronary-artery bypass surgery in stable angina pectoris: survival at two years. European coronary surgery study group. Lancet 1(8122):889\u2013893","DOI":"10.1016\/S0140-6736(79)91372-2"},{"key":"2800_CR69","doi-asserted-by":"crossref","unstructured":"Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH (1991) Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 114(10):835\u2013839","DOI":"10.7326\/0003-4819-114-10-835"},{"key":"2800_CR70","doi-asserted-by":"crossref","unstructured":"Chamberlain DA et al (1997) Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 350(9076):461\u2013468","DOI":"10.1016\/S0140-6736(97)07298-X"},{"key":"2800_CR71","doi-asserted-by":"crossref","unstructured":"Pedersen TR et al (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet 344(8934):1383\u20131389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"2800_CR72","doi-asserted-by":"crossref","unstructured":"Peduzzi et al (1992) Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Circulation 86(1):121\u2013130","DOI":"10.1161\/01.CIR.86.1.121"},{"issue":"2","key":"2800_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae009","volume":"4","author":"W Zheng","year":"2024","unstructured":"Zheng W, Huang X, Wang X, Suo M, Yan Y, Gong W et al (2024) Impact of multimorbidity patterns on outcomes and treatment in patients with coronary artery disease. Eur Heart J Open 4(2):oeae009","journal-title":"Eur Heart J Open"},{"issue":"1","key":"2800_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","volume":"151","author":"NWS Chew","year":"2025","unstructured":"Chew NWS, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B et al (2025) Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified delphi approach. Circulation 151(1):98\u2013119","journal-title":"Circulation"},{"key":"2800_CR75","unstructured":"Lopez-Candales A, Hern\u00e1ndez Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: from normal aging to the metabolic syndrome. J Nat Sci. 2017;3(4)."},{"issue":"1","key":"2800_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02552-0","volume":"24","author":"G Kong","year":"2025","unstructured":"Kong G, Koh J, Chia J, Neo B, Chen Y, Cao G et al (2025) A sex-disaggregated analysis of the prognostic value of lean type 2 diabetes mellitus in the adult population with acute myocardial infarction. Cardiovasc Diabetol 24(1):59","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2800_CR77","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.14950","volume":"25","author":"Y Chin","year":"2023","unstructured":"Chin Y, Lim J, Kong G, Ng CH, Goh R, Muthiah M et al (2023) Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. Diabetes Obes Metab 25(4):1032\u20131044","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2800_CR78","first-page":"1220","volume":"38","author":"NWS Chew","year":"2022","unstructured":"Chew NWS, Zhang A, Ong J, Koh S, Kong G, Ho YJ et al (2022) Long-term prognosis in patients with concomitant acute coronary syndrome and aortic stenosis. Can J Cardiol 38(8):1220\u20131227","journal-title":"Can J Cardiol"},{"key":"2800_CR79","doi-asserted-by":"crossref","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, De Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evidence. 2024;3(2).","DOI":"10.1056\/EVIDoa2300286"},{"issue":"24","key":"2800_CR80","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun Helen M, Deanfield J, Emerson Scott S, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389(24):2221\u20132232","journal-title":"N Engl J Med"},{"issue":"12","key":"2800_CR81","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/eurjpc\/zwad133","volume":"30","author":"CYL Yaow","year":"2023","unstructured":"Yaow CYL, Chong B, Chin YH, Kueh MTW, Ng CH, Chan KE et al (2023) Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes mellitus: an umbrella review of systematic reviews. Eur J Prev Cardiol 30(12):1227\u20131235","journal-title":"Eur J Prev Cardiol"},{"key":"2800_CR82","doi-asserted-by":"crossref","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation.0(0).","DOI":"10.1161\/CIR.0000000000001309"},{"issue":"2","key":"2800_CR83","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ehf2.13822","volume":"9","author":"T Yeong","year":"2022","unstructured":"Yeong T, Mai AS, Lim OZH, Ng CH, Chin YH, Tay P et al (2022) Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis. ESC Heart Fail 9(2):1338\u20131350","journal-title":"ESC Heart Fail"},{"issue":"15","key":"2800_CR84","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/2047487317729252","volume":"24","author":"SV Arnold","year":"2017","unstructured":"Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM et al (2017) Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00ae research to practice project. Eur J Prev Cardiol 24(15):1637\u20131645","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"2800_CR85","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","volume":"140","author":"SV Arnold","year":"2019","unstructured":"Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE et al (2019) Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation 140(7):618\u2013620","journal-title":"Circulation"},{"key":"2800_CR86","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2023.04.042","volume":"383","author":"VV Anand","year":"2023","unstructured":"Anand VV, Zhe ELC, Chin YH, Goh RSJ, Lin C, Kueh MTW et al (2023) Socioeconomic deprivation and prognostic outcomes in acute coronary syndrome: a meta-analysis using multidimensional socioeconomic status indices. Int J Cardiol 383:140\u2013150","journal-title":"Int J Cardiol"},{"issue":"5","key":"2800_CR87","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eprac.2022.10.006","volume":"29","author":"VV Anand","year":"2023","unstructured":"Anand VV, Zhe ELC, Chin YH, Lim WH, Goh RSJ, Lin C et al (2023) Barriers and facilitators to engagement with a weight management intervention in Asian patients with overweight or obesity: a systematic review. Endocr Pract 29(5):398\u2013407","journal-title":"Endocr Pract"},{"issue":"1","key":"2800_CR88","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gheart.2012.12.008","volume":"8","author":"MU Qazi","year":"2013","unstructured":"Qazi MU, Malik S (2013) Diabetes and cardiovascular disease: original insights from the Framingham heart study. Glob Heart 8(1):43\u201348","journal-title":"Glob Heart"},{"key":"2800_CR89","doi-asserted-by":"crossref","unstructured":"Neglia D, Caselli C, Maffei E, Cademartiri F, Meloni A, Bossone E, et al. Rapid plaque progression is independently associated with hyperglycemia and low HDL cholesterol in patients with stable coronary artery disease: a PARADIGM study. Circulation: Cardiovascular Imaging. 2024;17(7):e016481.","DOI":"10.1161\/CIRCIMAGING.123.016481"},{"issue":"2","key":"2800_CR90","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/eurjpc\/zwaa128","volume":"29","author":"D De Bacquer","year":"2022","unstructured":"De Bacquer D, Ueda P, Reiner \u017d, De Sutter J, De Smedt D, Lovic D et al (2022) Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE risk model. Eur J Prev Cardiol 29(2):328\u2013339","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"2800_CR91","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","volume":"125","author":"PW Wilson","year":"2012","unstructured":"Wilson PW, D\u2019Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC et al (2012) An international model to predict recurrent cardiovascular disease. Am J Med 125(7):695-703.e1","journal-title":"Am J Med"},{"issue":"12","key":"2800_CR92","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/2047487313501278","volume":"21","author":"G Ducrocq","year":"2020","unstructured":"Ducrocq G, Bhatt D, Labreuche J, Corbalan R, Porath A, Gao R et al (2020) Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH registry. Eur J Prev Cardiol 21(12):1509\u20131516","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"2800_CR93","doi-asserted-by":"publisher","first-page":"960","DOI":"10.4065\/mcp.2011.0010","volume":"86","author":"TA Meadows","year":"2011","unstructured":"Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, R\u00f6ther J, Goto S et al (2011) Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Mayo Clin Proc 86(10):960\u2013967","journal-title":"Mayo Clin Proc"},{"key":"2800_CR94","doi-asserted-by":"crossref","unstructured":"Magavern EF, Jacobs B, Warren H, Finocchiaro G, Finer S, van Heel DA, et al. CYP2C19 Genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel. JACC Adv. 2023;2(7):None.","DOI":"10.1016\/j.jacadv.2023.100573"},{"issue":"1","key":"2800_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s44325-024-00006-w","volume":"1","author":"C Krittanawong","year":"2024","unstructured":"Krittanawong C, Khawaja M, Virk HUH, Escobar J, Khalid U, Birnbaum Y et al (2024) Strategies for chronic coronary disease: a brief guide for clinicians. NPJ Cardiovasc Health 1(1):6","journal-title":"NPJ Cardiovasc Health"},{"issue":"3","key":"2800_CR96","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MCA.0000000000001086","volume":"33","author":"AB Abbadi","year":"2022","unstructured":"Abbadi AB, Lemesle G, Lamblin N, Bauters C (2022) Very long-term outcomes of older adults with stable coronary artery disease (from the CORONOR study). Coron Artery Dis 33(3):169\u2013175","journal-title":"Coron Artery Dis"},{"issue":"36","key":"2800_CR97","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45(36):3415\u20133537","journal-title":"Eur Heart J"},{"key":"2800_CR98","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02563-7","author":"VV Anand","year":"2024","unstructured":"Anand VV, Koh J, Teo T, Chin YH, Mahesh R, Chan MY et al (2024) Sex differences in survival following acute coronary syndrome with and without standard modifiable risk factors. Clin Res Cardiol. https:\/\/doi.org\/10.1007\/s00392-024-02563-7","journal-title":"Clin Res Cardiol"},{"key":"2800_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.869168","volume":"9","author":"G Kong","year":"2022","unstructured":"Kong G, Chew NWS, Ng CH, Chin YH, Lim OZH, Ambhore A et al (2022) Prognostic outcomes in acute myocardial infarction patients without standard modifiable risk factors: a multiethnic study of 8,680 Asian patients. Front Cardiovasc Med 9:869168","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"2800_CR100","first-page":"1539","volume":"39","author":"Y Hirao","year":"2023","unstructured":"Hirao Y, Seki T, Watanabe N, Matoba S (2023) Health-related quality of life after percutaneous coronary intervention for stable ischemic heart disease: a systematic review and meta-analysis. Can J Cardiol 39(11):1539\u20131548","journal-title":"Can J Cardiol"},{"key":"2800_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.822228","volume":"9","author":"NWS Chew","year":"2022","unstructured":"Chew NWS, Koh JH, Ng CH, Tan DJH, Yong JN, Lin C et al (2022) Coronary artery bypass grafting versus percutaneous coronary intervention for multivessel coronary artery disease: a one-stage meta-analysis. Front Cardiovasc Med 9:822228","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2800_CR102","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa072771","volume":"359","author":"WS Weintraub","year":"2008","unstructured":"Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C et al (2008) Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359(7):677\u2013687","journal-title":"N Engl J Med"},{"key":"2800_CR103","doi-asserted-by":"crossref","unstructured":"Chew NWS, Ng C-H, Kong G, Lee K-S, Tan DJH, Lim OZ-H, et al. Meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting for left main narrowing. The American Journal of Cardiology. 2022;173:39\u201347.","DOI":"10.1016\/j.amjcard.2022.02.044"},{"key":"2800_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101685","volume":"54","author":"YH Chin","year":"2022","unstructured":"Chin YH, Ng CH, Chew NW, Kong G, Lim WH, Tan DJH et al (2022) The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine 54:101685","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2800_CR105","first-page":"511","volume":"9","author":"YH Chin","year":"2023","unstructured":"Chin YH, Lim O, Lin C, Chan YY, Kong G, Ng CH et al (2023) Meta-analysis of the placebo and nocebo effects associated with placebo treatment in randomized trials of lipid-lowering therapies. Eur Heart J 9(5):511\u2013519","journal-title":"Eur Heart J"},{"issue":"3","key":"2800_CR106","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clinthera.2017.01.031","volume":"39","author":"V Chavarria","year":"2017","unstructured":"Chavarria V, Vian J, Pereira C, Data-Franco J, Fernandes BS, Berk M, Dodd S (2017) The placebo and nocebo phenomena: their clinical management and impact on treatment outcomes. Clin Ther 39(3):477\u2013486","journal-title":"Clin Ther"},{"issue":"1","key":"2800_CR107","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P (2007) The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 7(1):30","journal-title":"BMC Med Res Methodol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02800-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-025-02800-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-025-02800-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T08:02:49Z","timestamp":1764835369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-025-02800-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":107,"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1007\/s00392-025-02800-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.A.F. has received grants from the National Health and Medical Research Council (Australia), Abbott Diagnostic, Sanofi, Janssen Pharmaceuticals, and NSW Health. G.A.F. has received an honorarium from CSL, CPC Clinical Research, Sanofi, Boehringer-Ingelheim, Heart Foundation, and Abbott. G.A.F. serves as a Board Director for the Australian Cardiovascular Alliance (past President), Executive Committee Member for CPC Clinical Research, Founding Director and CMO for Prokardia and Kardiomics, and Executive Committee member for the CAD Frontiers A2D2 Consortium. In addition, G.A.F. serves as CMO for the non-profit, CAD Frontiers, with industry partners including, Novartis, Amgen, Siemens Healthineers, ELUCID, Foresite Labs LLC, HeartFlow, Canon, Cleerly, Caristo, Genentech, Artyra, and Bitterroot Bio, Novo Nordisk and Allelica. Additionally, G.A.F. has the following patents: \u201cPatent Biomarkers and Oxidative Stress\u201d awarded USA May 2017 (US9638699B2) issued to Northern Sydney Local Health District, \u201cUse of P2X7R antagonists in cardiovascular disease\u201d PCT\/AU2018\/050905 licensed to Prokardia, \u201cMethods for treatment and prevention of vascular disease\u201d PCT\/AU2015\/000548 issued to The University of Sydney\/Northern Sydney Local Health District, \u201cMethods for predicting coronary artery disease\u201d AU202290266 issued to The University of Sydney, and the patent \u201cNovel P2X7 Receptor Antagonists\u201d PCT\/AU2022\/051400 (23.11.2022), International App No: WO\/2023\/092175 (01.06.2023), issued to The University of Sydney.N.W.S.C has received research grant support from the NUHS Seed Fund (NUHSRO\/2022\/RO5\u2009+\u20096\/Seed-Mar\/03), the National Medical Research Council Research Training Fellowship (MH 095:003\/008\u2013303), National University of Singapore Yong Loo Lin School of Medicine\u2019s Academic Fellowship Scheme, the NUHS Clinician Scientist Program (NCSP2.0\/2024\/NUHS\/NCWS), the National Medical Research Council Transition Award (TA24jul-0008), and the CSDU Clinician-Scientist Grant.M.Y.C. receives speaker\u2019s fees and research grants from AstraZeneca, Abbott Technologies, and Boston Scientific.N.W. has received research fellowship funding from Abbott Vascular.A.M. has received grant funding from Novartis and Amgen.M.S.K. receives consulting fees from Bayer and Novartis.No conflict of interest declared for R.M., D.H.C.W, V.V.A, D.K.E.S., Y.R.H., Y.C., B.C., A.D.H., J.C., H.W.S., G.N., C.Y.K., P.H.L., M.A.M., and Y.H.C.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}